Full Text View
Tabular View
No Study Results Posted
Related Studies
A Study Evaluating the Safety of ABT-263 in Combination With Etoposide/Cisplatin in Subjects With Cancer
This study has been completed.
Study NCT00878449   Information provided by AbbVie

First Received on April 7, 2009.   Last Updated on January 24, 2013   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Solid Tumors
Interventions listed in this trial
ABT-263
etoposide/cisplatin
Additional drug interventions recognized in this trial
Cisplatin
Etoposide
Etoposide phosphate
More general drug interventions related to this trial
Antineoplastic Agents
Antineoplastic Agents, Phytogenic
Pharmacologic Actions
Physiological Effects of Drugs
Radiation-Sensitizing Agents
Therapeutic Uses
Sponsors listed in this trial
AbbVie (prior sponsor, Abbott)
Genentech


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services